Pre-Clinical Data with ALN-GO1, in Development for the Treatment of Primary Hyperoxaluria Type 1

Pre-Clinical Data with ALN-GO1, in Development for the Treatment of Primary Hyperoxaluria Type 1

We presented new pre-clinical data supporting the selection of a Development Candidate (DC) for ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase (GO), also referred to as hydroxyacid oxidase 1 (HAO1), for the treatment of primary hyperoxaluria type 1 (PH1).  These data were presented at the 48th European Society of Paediatric Nephrology (ESPN) Annual meeting – held September 3 – 5, 2015, in Brussels – showing up to 99% silencing of the HAO1 mRNA and up to 98% mean reduction of urinary oxalate in animal models of PH1.



We believe that ALN-GO1 represents a truly innovative approach for the treatment of PH1, an ultra-rare orphan disease with enormous unmet need as there are no approved therapeutics available.  From our ongoing human experience with ESC-GalNAc conjugates, we believe that ALN-GO1 has the potential to achieve a once monthly, and possibly once quarterly, subcutaneous dose regimen with a favorable tolerability profile. We look forward to the continued advancement of this novel investigational therapeutic.



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.